Save time and get answers to complex questions with AI chat
Mobic injection patent oehringer ingelheim france?When did risperdal constas patent expire published article?Tenofovir generic patent?Somatuline generic name?Pramlintide acetate price?
See the DrugPatentWatch profile for Tagrisso
Tagrisso (osimertinib) was first approved by the FDA on November 13, 2015, for metastatic EGFR T790M mutation–positive NSCLC after progression on EGFR-TKI therapy (accelerated approval). If you need the approval date for a specific indication (e.g., first-line use, adjuvant setting), tell me which one and I’ll pull that date.
Other Questions About Tagrisso :